TcVac3 Induced Control of Trypanosoma cruzi Infection and Chronic Myocarditis in Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Gupta, Shivali ^a   Garg, Nisha Jain ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MODIFIED VACCINIA ANKARA TRYPANOSOMA CRUZI G2 G4 ANTIGEN VACCINE; PERFORIN; PROTOZOAL VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; EFFECTOR CELL; FEMALE; HEART MUSCLE FIBROSIS; HEART PROTECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RESISTANCE; INFLAMMATORY INFILTRATE; LYMPHOCYTE PROLIFERATION; MOUSE; MYOCARDITIS; MYOFIBROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE LOCALIZATION; PARASITISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CHAGAS CARDIOMYOPATHY; CHRONIC DISEASE; CYTOKINES; FEMALE; IMMUNIZATION, SECONDARY; MICE; PROTOZOAN VACCINES; TRYPANOSOMA CRUZI; VACCINATION; VACCINES, DNA; VIRAL VACCINES;

MUS; TRYPANOSOMA CRUZI;

EID: 84875463493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059434     Document Type: Article

References (48)

1. World Health Organization (2010) Chagas disease: control and elimination. UNDP/World Bank/WHO. Available: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_17-en.pdf. Accessed 2013 February 28.
2. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV, (2007) Pathogenesis of chronic Chagas heart disease. Circulation 115: 1109-1123.
3. Bonney KM, Engman DM, (2008) Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 8: 510-518.
4. Bhatia V, Wen J-J, Zacks MA, Garg NJ (2009) American trypanosomiasis and perspectives on vaccine development, Stanberry, L.R. Barrett, A.D., book title: Vaccines for Biodefense and Emerging and Neglected Diseases Academic Press NY p1407-1434 p.
5. Vazquez-Chagoyan JC, Gupta S, Garg NJ, (2011) Vaccine development against Trypanosoma cruzi and Chagas disease. Adv Parasitol 75: 121-146.
6. Cazorla SI, Becker PD, Frank FM, Ebensen T, Sartori MJ, et al. (2008) Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun 76: 324-333.
7. Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, et al. (2005) Immune responses against a single CD8+ T cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 73: 7356-7365.
8. de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, et al. (2009) Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 77: 4383-4395.
9. Bhatia V, Garg NJ, (2008) Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol 15: 1158-1164.
10. Aparicio-Burgos JE, Ochoa-Garcia L, Zepeda-Escobar JA, Gupta S, Dhiman M, et al. (2011) Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs. PLoS Negl Trop Dis 5: e1050.
11. Gupta S, Garg NJ, (2010) Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis 4: e797.
12. Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, et al. (2007) Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 366: 84-97.
13. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, et al. (2008) Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198: 1482-1490.
14. Drexler I, Staib C, Sutter G, (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15: 506-512.
15. Gupta S, Garg NJ, (2012) Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8+T cell mediated immunity against Trypanosoma cruzi. Vaccine 12: 1464-1478.
16. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, et al. (2006) Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24: 4554-4561.
17. Meseda CA, Elkins KL, Merchlinsky MJ, Weir JP, (2002) Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis 186: 1065-1073.
18. Bhatia V, Sinha M, Luxon B, Garg NJ, (2004) Utility of Trypanosoma cruzi sequence database for the identification of potential vaccine candidates: In silico and in vitro screening. Infect Immun 72: 6245-6254.
19. Namujju PB, Hedman L, Hedman K, Banura C, Mbidde EK,et al. Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence. BMC Res Notes 4: 170.
20. Narita M, Matsuzono Y, Takekoshi Y, Yamada S, Itakura O, et al. (1998) Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol. 5: 799-803.
21. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
22. Garg NJ, Bhatia V, Gerstner A, deFord J, Papaconstantinou J, (2004) Gene expression analysis in mitochondria from chagasic mice: Alterations in specific metabolic pathways. Biochemical J 381: 743-752.
23. Dhiman M, Garg NJ, (2011) NADPH oxidase inhibition ameliorates Trypanosoma cruzi-induced myocarditis during Chagas disease. J Pathol 225: 583-596.
24. Nogueira N, Ellis J, Chaplan S, Cohn Z, (1981) Trypanosoma cruzi: in vivo and in vitro correlation between T-cell activation and susceptibility in inbred strains of mice. Exp Parasitol 51: 325-334.
25. Chen L, Watanabe T, Watanabe H, Sendo F, (2001) Neutrophil depletion exacerbates experimental Chagas' disease in BALB/c, but protects C57BL/6 mice through modulating the Th1/Th2 dichotomy in different directions. Eur J Immunol 31: 265-275.
26. Rocha CD, Caetano BC, Machado AV, Bruna-Romero O, (2004) Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7: 83-94.
27. Souza AP, Haut L, Reyes-Sandoval A, Pinto AR, (2005) Recombinant viruses as vaccines against viral diseases. Braz J Med Biol Res 38: 509-522.
28. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, et al. (2008) Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 118: 1776-1784.
29. Vasconcelos JR, Boscardin SB, Hiyane MI, Kinoshita SS, Fujimura AE, et al. (2003) A DNA-priming protein-boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain. Immunol Cell Biol 81: 121-129.
30. Vasconcelos JR, Hiyane MI, Marinho CR, Claser C, Machado AM, et al. (2004) Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 15: 878-886.
31. Planelles L, Thomas MC, Alonso C, Lopez MC, (2001) DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun 69: 6558-6563.
32. Marcipar IS, Risso MG, Silber AM, Revelli S, Marcipar AJ, (2001) Antibody maturation in Trypanosoma cruzi-infected rats. Clin Diagn Lab Immunol 8: 802-805.
33. Cordeiro FD, Martins-Filho OA, Da Costa Rocha MO, Adad SJ, Correa-Oliveira R, et al. (2001) Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clin Diagn Lab Immunol 8: 112-118.
34. Galvao LM, Nunes RM, Cancado JR, Brener Z, Krettli AU, (1993) Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg 87: 220-223.
35. Bernasconi NL, Traggiai E, Lanzavecchia A, (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.
36. Montes CL, Acosta-Rodriguez EV, Merino MC, Bermejo DA, Gruppi A, (2007) Polyclonal B cell activation in infections: infectious agents' devilry or defense mechanism of the host? J Leukoc Biol 82: 1027-1032.
37. Costa RP, Gollob KJ, Fonseca LL, Rocha MO, Chaves AC, et al. (2000) T-cell repertoire analysis in acute and chronic human Chagas disease: differential frequencies of Vbeta5 expressing T cells. Scand J Immunol 51: 511-519.
38. Souza PE, Rocha MO, Rocha-Vieira E, Menezes CA, Chaves AC, et al. (2004) Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun 72: 5283-5291.
39. Souza PE, Rocha MO, Menezes CA, Coelho JS, Chaves AC, et al. (2007) Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease. Infect Immun 75: 1886-1894.
40. McCabe R, Meagher S, Mullins B, (1991) Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice. Infect Immun 59: 1633-1638.
41. Reed SG, (1988) In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol 140: 4342-4347.
42. Cunha-Neto E, Dzau VJ, Allen PD, Stamatiou D, Benvenutti L, et al. (2005) Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. Am J Pathol 167: 305-313.
43. Drigo SA, Cunha-Neto E, Ianni B, Cardoso MR, Braga PE, et al. (2006) TNF gene polymorphisms are associated with reduced survival in severe Chagas disease cardiomyopathy patients. Microbes Infect 8: 598-603.
44. Araujo FF, Gomes JA, Rocha MO, Williams-Blangero S, Pinheiro VM, et al. (2007) Potential role of CD4+CD25hi regulatory T cells in morbidity in Chagas disease. Front Biosci 12: 2797-2806.
45. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, et al. (2006) Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24: 3026-3034.
46. Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, et al. (2006) Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24: 4709-4715.
47. Dorrell L, Williams P, Suttill A, Brown D, Roberts J, et al. (2007) Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25: 3277-3283.
48. Burgers WA, Shephard E, Monroe JE, Greenhalgh T, Binder A, et al. (2008) Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses. 24: 195-206.